23andMe deal should never be cloned
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.
By Robert Cyran
NEW YORK, Sept 20 (Reuters Breakingviews) -The double helix that was 23andMe’s ME.O board of directors and company’s founder Anne Wojcicki unraveled on Tuesday. The entire committee, save Wojcicki, resigned in frustration over her stalled takeover bid. But the offer is perhaps the least-worst detail of this saga. From start-to-finish, 23andMe’s venture onto the public markets should never be cloned.
The company takes genetic samples from customers and tells them where their ancestors came from, helps find relatives, and shows whether a customer is a carrier of gene variants causing diseases. It went public in 2021 via a special-purpose acquisition company backed by British billionaire Richard Branson. At the time it gave 23andMe an implied enterprise value of $3.5 billion.
23andMe had just over $300 million of annual revenue and adjusted EBITDA loss of $147 million. There was some promise: statements in the deal pitchbook outlined plans to “revolutionize the diagnosis, prevention and treatment of most, if not all, of human disease." But the company oversold what the technology could deliver. Financial projections of $400 million of revenue for the fiscal year ending in March 2024 were equally fantastical.
There’s little prospect of improvement. 23andMe’s operations burn cash - over $40 million last quarter - so its $170 million hoard won’t last too long. There’s not much customer incentive to repeat testing or pay for a subscription. Sure, the company has accumulated a trove of genetic data. Snag is, it’s hard to turn this into profit. Its drug discovery business has a few potential therapies, but such assets tend to attract little interest from investors. A recent data breach and settlement dinged the company’s reputation.
Enter Wojcicki, who offered 40 cent per share in July, the same price as the stock was trading at before her bid. The deal has other warts too, like a lack of financing. Still, a better offer probably isn’t forthcoming, and the shares closed on Thursday at 33 cents. The shareholder alternative may be eventual bankruptcy.
The problem is that Wojcicki has a 49% voting stake thanks to class B shares with 10 votes each. The board tried to take a decently hard line, asking for more assurances that her offer was financed, or if Wojcicki would consider other strategic directions for the company, according to a person familiar with the former directors’ thinking. When they thought neither were likely to happen, the members resigned.
By the time this deal had come around, though, the genetic makeup of 23andMe had already been tainted. Wojcicki’s super-voting stock was something investors and board members were willing to overlook when the company’s prospects were bright. But it primed the company for its governance implosion when trouble mounted. Same goes for a half-baked public listing. Directors can walk, and shareholders can sell, but those are unsatisfactory responses to a CEO in flounder mode.
Follow @rob_cyran on X
CONTEXT NEWS
All seven independent directors on 23andMe’s board resigned on Sept. 17, leaving Anne Wojcicki, the company’s chief executive officer and co-founder, as the only remaining board member.
Wojcicki offered to take the company private in July, but that offer was rejected by a special committee formed by the board, because it said the 40 cents per share offer didn’t provide a premium to the stock’s trading price and was not fully financed. Super-voting stock gives Wojcicki 49.8% of the vote.
The directors said they had yet to receive a fully financed and acceptable offer, did not believe one was coming, and therefore were unwilling to consider further extensions. The directors that resigned are Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller, and Peter J. Taylor.
In a statement, Wojcicki said she continued to believe that taking the company private was the best path to success, and that 23andMe would immediately begin to identify new independent directors to the board.
Graphic: 23andMe's revenue projections fell far short https://reut.rs/3XAuMm0
Editing by Lauren Silva Laughlin and Sharon Lam
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
